A Phase 3 interventional study of RSVPreF3 OA vaccine and FLU vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 37 sites in 5 countries. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-24.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 7th largest by enrollment, is one of 3 that started in 2022, is one of 15 in phase 3, and was the 6th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2022.
This study's enrollment of 1,045 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 14th largest by enrollment, is one of 5 that started in 2022, is one of 21 in phase 3, and was the 26th registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess the immunogenicity, safety and reactogenicity of the RSV PreFusion protein 3 older adult (RSVPreF3 OA) investigational vaccine when co-administered with an adjuvanted quadrivalent influenza (FLU aQIV) vaccine, in adults aged 65 years of age (YOA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical conditions
Prior/Concomitant therapy
Prior/Concurrent clinical study experience
Other exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received one dose of FLU-aQIV vaccine and one dose of RSVPreF3 OA vaccine, both doses administered at Day 1, and were followed until end of study.
Biological: RSVPreF3 OA vaccine · Biological: FLU vaccine
Participants received one dose of FLU-aQIV vaccine at Day 1, followed by one dose of RSVPreF3 OA vaccine at Day 31, and were followed until end of study.
Biological: RSVPreF3 OA vaccine · Biological: FLU vaccine
One dose of RSVPreF3 OA vaccine administered intramuscularly.
One dose of FLU vaccine administered intramuscularly.
Also known as: Fluad Tetra, FLUAD QUADRIVALENT, Fluad Quad
Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 FLU Vaccine Strains Expressed as Group Geometric Mean Titers (GMTs) at 1 Month After FLU Vaccine Dose
HI antibodies assessed were antibodies against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata flu strains.
Time frame: At 1 month after the FLU vaccine dose (Day 31 for both groups)
RSV-A Neutralizing Antibody Titers Expressed as GMTs
RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dilution 60 (ED60).
Time frame: At 1 month after the RSVPreF3 OA dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)
RSV-B Neutralizing Antibody Titers Expressed as GMTs
RSV B neutralizing antibodies are given as GMTs and expressed as Estimated Dilution 60 (ED60).
Time frame: At 1 month after the RSVPreF3 OA dose (Day 31 for the CoAd Group and Day 61 for the Control Group)
HI Seroconversion Rate (SCR) for 4 FLU Vaccine Strains
SCR for HI antibody is defined as the percentage of participants who have either a HI predose titer less than (\<) 1:10 and a post-dose titer greater than or equal to (\>=) 1:40, or a pre-dose titer \>= 1:10 and at least a 4-fold increase in post-dose titer. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.
Time frame: At 1 month after the FLU vaccine dose (Day 31 for both groups)
RSV-A Neutralization Antibody Titers Expressed as Mean Geometric Increase (MGI)
MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.
Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group) compared to pre-vaccination (Day 1 for Co-Ad group and Day 31 for Control group)
RSV-B Neutralization Antibody Titers Expressed as MGI
MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.
Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group) compared to pre-vaccination (Day 1 for Co-Ad group and Day 31 for Control group)
Titers for HI Antibodies Against 4 FLU Vaccine Strains
HI antibodies assessed were antibodies against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata flu strains. HI antibodies were expressed as GMT, in titers.
Time frame: At Day 1 (Baseline) and Day 31
HI Seroprotection Rate (SPR) for 4 FLU Vaccine Strains
SPR for HI antibody was defined as the percentage of participants with a serum HI titer \>= 1:40. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.
Time frame: At Day 1 (Baseline) and Day 31
HI Antibody Titers for 4 FLU Vaccine Strains Expressed as MGI
MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.
Time frame: At 1 month after the FLU dose (Day 31 for both groups) compared to pre-vaccination (Day 1 for both groups)
Percentage of Participants Reporting Each Solicited Administration Site Event After Each Vaccine Dose Administration
The solicited administration site events after vaccination include erythema, pain and swelling.
Time frame: Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Day 1 for CoAd Group and at Day 1 and Day 31 for Control group)
Percentage of Participants Reporting Each Solicited Systemic Event After Each Dose Administration
The solicited systemic events after vaccination include fever, headache, fatigue, myalgia and arthralgia.
Time frame: Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Day 1 and Day 31 for C-oAd Group and at Day 1 and Day 31 for Control group)
Percentage of Participants Reporting Unsolicited Adverse Events (AEs)
An unsolicited AEs is an AE that is not included in a list of solicited events using a Participant Electronic Diary. Unsolicited events must be spontaneously communicated by a participant who signs the informed consent. Unsolicited AEs include both serious, non-serious AEs and potential immune-mediated diseases (pIMDs).
Time frame: Within 30 days (the day of vaccination and 29 subsequent days) after each vaccine administration
Percentage of Participants Reporting at Least One Serious Adverse Event (SAEs)
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant.
Time frame: From Day 1 until 6 months after last vaccination (Month 6 for the Co-Ad Group, Month 7 for the Control group)
Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMDs)
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. The investigator must exercise his/her medical/scientific judgment to determine whether other diseases have an autoimmune origin (i.e., pathophysiology involving systemic or organ-specific pathogenic autoantibodies) and should also be recorded as a pIMD.
Time frame: From Day 1 until 6 months after last vaccination (Month 6 for the Co-Ad Group, Month 7 for the Control group)
All 1045 enrolled participants were randomized to Co-Ad and Control Groups and received at least 1 dose of study intervention and were included in the exposed set.
| Milestone | Co-Ad Group | Control Group |
|---|---|---|
| Started | 523 | 522 |
| Completed | 518 | 499 |
| Not completed | 5 | 23 |
| Withdrew: Adverse event | 0 | 8 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Withdrawal by subject | 1 | 10 |
| Withdrew: Other | 2 | 2 |
HI antibodies assessed were antibodies against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata flu strains.
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Darwin/6/2021 H3N2 | 43.8 (38.9 to 49.4) | 57.7 (51.0 to 65.3) |
| Flu A/Victoria/2570/2019 H1N1 | 143.0 (128.6 to 159.0) | 148.5 (133.2 to 165.6) |
| Flu B/Austria/1359417/2021 Victoria | 613.9 (575.1 to 655.2) | 597.5 (558.7 to 639.1) |
| Flu B/Phuket/3073/2013 Yamagata | 406.2 (380.0 to 434.2) | 421.0 (393.0 to 451.0) |
RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dilution 60 (ED60).
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| RSV-A Neutralizing Antibody Titers Expressed as GMTs | 6673.4 (6057.2 to 7352.4) | 6591.8 (5917.8 to 7342.6) |
RSV B neutralizing antibodies are given as GMTs and expressed as Estimated Dilution 60 (ED60).
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| RSV-B Neutralizing Antibody Titers Expressed as GMTs | 7880.1 (7195.4 to 8629.8) | 9134.1 (8255.9 to 10105.7) |
SCR for HI antibody is defined as the percentage of participants who have either a HI predose titer less than (\<) 1:10 and a post-dose titer greater than or equal to (\>=) 1:40, or a pre-dose titer \>= 1:10 and at least a 4-fold increase in post-dose titer. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Darwin/6/2021 H3N2 | 51.7 (46.9 to 56.6) | 62.0 (57.0 to 66.8) |
| Flu A/Victoria/2570/2019 H1N1 | 44.0 (39.2 to 48.9) | 45.7 (40.7 to 50.8) |
| Flu B/Austria/1359417/2021 Victoria | 17.2 (13.8 to 21.2) | 17.5 (13.9 to 21.6) |
| Flu B/Phuket/3073/2013 Yamagata | 18.5 (14.9 to 22.5) | 19.3 (15.5 to 23.5) |
MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.
| Ratio | Co-Ad Group | Control Group |
|---|---|---|
| RSV-A Neutralization Antibody Titers Expressed as Mean Geometric Increase (MGI) | 8.50 (7.79 to 9.27) | 7.58 (6.82 to 8.42) |
MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.
| Ratio | Co-Ad Group | Control Group |
|---|---|---|
| RSV-B Neutralization Antibody Titers Expressed as MGI | 7.11 (6.55 to 7.72) | 7.46 (6.74 to 8.25) |
HI antibodies assessed were antibodies against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata flu strains. HI antibodies were expressed as GMT, in titers.
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Darwin/6/2021 H3N2, Day 1 | 9.1 (8.4 to 9.8) | 8.7 (8.1 to 9.4) |
| Flu A/Darwin/6/2021 H3N2 , Day 31 | 45.3 (40.6 to 50.5) | 58.3 (51.6 to 65.8) |
| Flu A/Victoria/2570/2019 H1N1, Day 1 | 40.0 (35.4 to 45.1) | 43.2 (38.4 to 48.5) |
| Flu A/Victoria/2570/2019 H1N1, Day 31 | 151.0 (136.4 to 167.2) | 163.8 (147.5 to 181.9) |
| Flu B/Austria/1359417/2021 Victoria, Day 1 | 323.6 (300.4 to 348.5) | 327.2 (303.6 to 352.7) |
| Flu B/Austria/1359417/2021 Victoria, Day 31 | 614.9 (575.5 to 657.0) | 608.1 (566.8 to 652.5) |
| Flu B/Phuket/3073/2013 Yamagata, Day 1 | 213.1 (198.5 to 228.7) | 193.2 (179.9 to 207.5) |
| Flu B/Phuket/3073/2013 Yamagata, Day 31 | 423.0 (394.6 to 453.5) | 417.5 (387.9 to 449.4) |
SPR for HI antibody was defined as the percentage of participants with a serum HI titer \>= 1:40. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Darwin/6/2021 H3N2, Day 1 | 10.4 (7.8 to 13.6) | 10.7 (8.0 to 13.9) |
| Flu A/Darwin/6/2021 H3N2, Day 31 | 63.6 (58.9 to 68.1) | 71.0 (66.3 to 75.4) |
| Flu A/Victoria/2570/2019 H1N1, Day 1 | 60.0 (55.4 to 64.5) | 64.3 (59.7 to 68.8) |
| Flu A/Victoria/2570/2019 H1N1, Day 31 | 92.0 (89.1 to 94.4) | 95.2 (92.7 to 97.1) |
| Flu B/Austria/1359417/2021 Victoria, Day 1 | 99.6 (98.5 to 99.9) | 100 (99.2 to 100) |
| Flu B/Austria/1359417/2021 Victoria, Day 31 | 100 (99.2 to 100) | 100 (99.1 to 100) |
| Flu B/Phuket/3073/2013 Yamagata, Day 1 | 99.8 (98.8 to 100.0) | 98.9 (97.4 to 99.6) |
| Flu B/Phuket/3073/2013 Yamagata, Day 31 | 100 (99.2 to 100) | 100 (99.1 to 100) |
MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.
| Ratio | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Darwin/6/2021 H3N2 HI | 5.10 (4.60 to 5.66) | 6.87 (6.12 to 7.71) |
| Flu A/Victoria/2570/2019 H1N1 HI | 3.85 (3.40 to 4.35) | 3.79 (3.34 to 4.31) |
| Flu B/Austria/1359417/2021 Victoria HI | 1.89 (1.77 to 2.03) | 1.84 (1.71 to 1.98) |
| Flu B/Phuket/3073/2013 Yamagata HI | 1.94 (1.82 to 2.07) | 2.11 (1.97 to 2.27) |
The solicited administration site events after vaccination include erythema, pain and swelling.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Erythema, FLU dose given at Day 1 | 6.6 (4.6 to 9.1) | 5.3 (3.5 to 7.6) |
| Erythema, RSV dose given at Day 1 | 14.1 (11.3 to 17.5) | — |
| Erythema, RSV dose given at Day 31 | — | 12.4 (9.5 to 15.8) |
| Pain, FLU dose given at Day 1 | 51.7 (47.3 to 56.1) | 44.8 (40.5 to 49.3) |
| Pain, RSV dose given at Day 1 | 66.1 (61.8 to 70.2) | — |
| Pain, RSV dose given at Day 31 | — | 58.8 (54.1 to 63.3) |
| Swelling, FLU dose given at Day 1 | 5.2 (3.5 to 7.5) | 6.0 (4.1 to 8.5) |
| Swelling, RSV dose given at Day 1 | 10.5 (8.0 to 13.4) | — |
| Swelling, RSV dose given at Day 31 | — | 8.4 (6.0 to 11.4) |
The solicited systemic events after vaccination include fever, headache, fatigue, myalgia and arthralgia.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Arthralgia, Dosing at Day 1 | 25.8 (22.1 to 29.8) | 15.6 (12.6 to 19.0) |
| Arthralgia, Dosing at Day 31 | — | 17.1 (13.7 to 20.9) |
| Fatigue, Dosing at Day 1 | 45.7 (41.4 to 50.1) | 28.5 (24.6 to 32.6) |
| Fatigue, Dosing at Day 31 | — | 30.4 (26.2 to 34.9) |
| Fever, Dosing at Day 1 | 2.1 (1.1 to 3.8) | 0.6 (0.1 to 1.7) |
| Fever, Dosing at Day 31 | — | 1.1 (0.4 to 2.6) |
| Headache, Dosing at Day 1 | 32.2 (28.2 to 36.4) | 19.3 (16.0 to 23.0) |
| Headache, Dosing at Day 31 | — | 23.9 (20.1 to 28.2) |
| Myalgia, Dosing at Day 1 | 39.0 (34.7 to 43.3) | 23.0 (19.4 to 26.9) |
| Myalgia, Dosing at Day 31 | — | 31.9 (27.6 to 36.5) |
An unsolicited AEs is an AE that is not included in a list of solicited events using a Participant Electronic Diary. Unsolicited events must be spontaneously communicated by a participant who signs the informed consent. Unsolicited AEs include both serious, non-serious AEs and potential immune-mediated diseases (pIMDs).
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Percentage of Participants Reporting Unsolicited Adverse Events (AEs) | 13.6 (10.8 to 16.8) | 24.5 (20.9 to 28.4) |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Percentage of Participants Reporting at Least One Serious Adverse Event (SAEs) | 4.0 (2.5 to 6.1) | 6.9 (4.9 to 9.4) |
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. The investigator must exercise his/her medical/scientific judgment to determine whether other diseases have an autoimmune origin (i.e., pathophysiology involving systemic or organ-specific pathogenic autoantibodies) and should also be recorded as a pIMD.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMDs) | 0 (0 to 0.7) | 0.6 (0.1 to 1.7) |
Collected over Solicited AEs were collected during 7-day follow-up period after each vaccination. Unsolicited AEs were ollected during 30-day follow-up period after each vaccination. SAEs and pIMDs were collected throughout the study period (from Day 1 to study end [6 months after last vaccination]).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Co-Ad Group | 0/523 (0%) | 21/523 (4%) | 427/523 (81.6%) |
| Control Group | 6/522 (1.1%) | 36/522 (6.9%) | 428/522 (82%) |
| Event | Co-Ad Group | Control Group |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/523 | 3/522 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/523 | 3/522 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 0/523 | 2/522 |
| BronchitisInfections and infestations | 2/523 | 0/522 |
| COVID-19Infections and infestations | 2/523 | 0/522 |
| Atrial fibrillationCardiac disorders | 2/523 | 1/522 |
| Infective exacerbation of chronic obstructive airways diseaseInfections and infestations | 1/523 | 1/522 |
| Respiratory syncytial virus infectionInfections and infestations | 1/523 | 1/522 |
| Respiratory tract infectionInfections and infestations | 1/523 | 1/522 |
| Complicated appendicitisInfections and infestations | 0/523 | 1/522 |
| Event | Co-Ad Group | Control Group |
|---|---|---|
| Injection site painGeneral disorders | 368/523 | 349/522 |
| FatigueGeneral disorders | 236/523 | 212/522 |
| MyalgiaMusculoskeletal and connective tissue disorders | 201/523 | 206/522 |
| HeadacheNervous system disorders | 167/523 | 164/522 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 133/523 | 133/522 |
| Injection site erythemaGeneral disorders | 83/523 | 76/522 |
| Injection site swellingGeneral disorders | 67/523 | 61/522 |
| NasopharyngitisInfections and infestations | 13/523 | 15/522 |
| COVID-19Infections and infestations | 11/523 | 14/522 |
| PyrexiaGeneral disorders | 14/523 | 9/522 |
| Age, Continuous(YEARS) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| Mean | 72.1 ± 5.4 | 72.2 ± 5.2 | 72.2 ± 5.3 |
| Sex: Female, Male(Participants) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| Female | 255 | 275 | 530 |
| Male | 268 | 247 | 515 |
| Race/Ethnicity, Customized(Participants) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 0 | 1 | 1 |
| Black or African American | 0 | 1 | 1 |
| White | 522 | 516 | 1038 |
| Multiple | 0 | 1 | 1 |
| Other - Unspecified | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Oct 2022 to primary completion in Feb 2023, 4 months.
Results were first posted in Mar 2024, 1 year after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 4 months is below that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arexvy
Respiratory Syncytial Virus Infections →